The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
Why one state’s plan to unwind a Medicaid rule is raising red flags
Where a good night’s sleep is hard to get
The surgeon general wants to talk to you about mental health
PBM reform effort intensifies on Capitol Hill
CDC heads to Ohio
The nursing home booster problem
FDA advisers recommend over-the-counter naloxone
What's new in psychedelics research
Making public the private equities associated with nursing homes
A step toward better data sharing
Contrarian scientists question Biden’s cancer moonshot
Could these new legal theories reverse abortion bans?
Court could ban abortion pills nationwide
Teen drug deaths lead California schools to stock overdose reversal drug
Former FDA chief David Kessler reflects on Covid
More regulation could be coming for cannabis
FTC cracks down on GoodRx
Deciding the fate of millions on Medicaid
The end of the Covid emergency is near, and Pfizer reveals its post-PHE plans
Lobbyists quake as Sanders takes Senate panel's helm
Create your
podcast in
minutes
It is Free